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Abstract 
Older individuals may be more susceptible
to cognitive side effects of antiepileptic drugs
than  are  younger  adults.  This  randomized,
double-blind  study  compared  the  cognitive
effects  of  lamotrigine  (median  maintenance
dosage, 500.0 mg/d) and topiramate (median
maintenance dosage, 300.0 mg/d) as adjunc-
tive therapy for 16 weeks in patients ≥50 years
of age. Fifty-one patients (lamotrigine, n=25;
topiramate,  n=26)  were  enrolled,  and  28
patients  (lamotrigine,  n=15;  topiramate,
n=13)  completed  the  study.  In  a  combined
analysis  of  all  cognitive  tests  performed,  no
significant  differences  between  treatment
groups were noted. However, analyses of indi-
vidual cognitive test results revealed that lam-
otrigine-treated patients had significantly bet-
ter  results  on  the  Controlled  Oral  Word
Association  Test  and  the  Symbol-Digit
Modalities  Test,  whereas  topiramate-treated
patients  had  significantly  more  favorable
results on the Digit Cancellation Test and the
Rey  Auditory-Verbal  Learning  Test.  Larger
studies are needed to further clarify the differ-
ences in the cognitive effects of lamotrigine
and topiramate in older patients.
Introduction
In comparison to younger adults, older indi-
viduals tend to be more susceptible to cogni-
tive  side  effects  of  antiepileptic  drug  (AED)
therapy.
1-4 Some cognitive functions, such as
memory,  may  already  be  declining  in  older
patients, which may make such patients less
tolerant  of  cognitive  side  effects  associated
with AEDs.
2,3 Additionally, age-related changes
in  AED  metabolism  and  pharmacokinetics
occur, such as decreased plasma protein bind-
ing, decreased renal drug clearance, decreased
hepatic oxidation, and longer elimination half-
life,
2,5 which may influence patients’ suscepti-
bility  to  cognitive  effects  of  AEDs.  Older
patients are also more likely to be receiving
multiple medications for comorbid conditions,
thereby  increasing  the  possibility  of  drug
interactions
1 and  possibly  affecting  patients’
susceptibility to cognitive side effects.
Cognitive effects differ between the various
AEDs. Although there are no clinical studies
comparing the cognitive side effects of AEDs
in older patients with epilepsy, many compara-
tive  studies  were  performed  in  younger
patients. For example, previous studies sug-
gested  that  lamotrigine  was  less  commonly
associated with the cognitive impairment that
was seen with many other AEDs and topira-
mate may pose cognitive side effects.
6,7Also the
results from a more recent study which com-
pared retention rates among newer AEDs sug-
gested  that  drug  discontinuations  for  word-
finding difficulties were more common with
topiramate than with any other drug studied.
8
In addition, a randomized, double-blind study
by Blum et al.
9 compared the cognitive effects
of lamotrigine and topiramate administered as
adjunctive therapy in adults with epilepsy, and
the results showed greater cognitive impair-
ment  associated  with  topiramate  therapy.
However,  it  is  not  well  understood  whether
older patients would experience different cog-
nitive side effects than younger adults, and if
so, how they would differ. 
Materials and Methods
Study participants
To be eligible for study inclusion, patients
were required to have had a confident diagno-
sis of partial epilepsy for ≥6 months and to
have had at least one complex partial or sec-
ondarily generalized tonic-clonic seizure (but
no more than 8 seizures per month) in the past
three  months.  This  study  included  patients
who are 50 years of age or older. Patients were
also required to be receiving carbamazepine or
phenytoin as monotherapy or in combination
with  one  additional  AED  that  is  neither  an
enzyme inducer nor inhibiter and to have had
no change of >10% in AED dose for at least one
month before study enrollment. Patients with
previous  exposure  to  lamotrigine  or  topira-
mate were excluded from the study. The proto-
col  and  informed  consent  were  approved  by
Institutional Review Boards for each site. All
patients provided written informed consent.
Study design
This randomized, double-blind, multicenter
study  began  with  a  screening  phase  of  ≤2
weeks, during which patients were screened
for eligibility and were administered a battery
of cognitive tests to establish baseline scores.
After the screening phase, patients were ran-
domly assigned, in a 1:1 ratio, to receive either
lamotrigine or topiramate as add-on therapy.
Drug dosages were titrated to a target mainte-
nance dosage during an 8-week dose escala-
tion  phase  (Table  1).  The  dose  escalation
phase was followed by an 8-week maintenance
phase, during which stable dosages of lamot-
rigine  or  topiramate  and  concomitant  AEDs
were maintained.
Study end points
The primary end point of the study was the
change from baseline to the end of the main-
tenance phase (Week 16) in the combined
analysis of the following measures of cogni-
tive function:
• Controlled Oral Word Association (COWA)
Test
10 of verbal fluency;
• Stroop  Color-Word  Interference  Test
11 of
reading speed and interference;
• Digit  Cancellation  Test
12 (a  timed  detec-
tion  task  that  evaluates  selective  atten-
tion);
• Lafayette  Grooved  Pegboard  Test  (domi-
nant hand)
13 of coordinated motor speed;
• Rey  Auditory-Verbal  Learning  Test
(RAVLT)
14 of delayed recall of verbal mem-
ory;
• Symbol-Digit  Modalities  Test
15 (a  timed
graphomotor coding task).
Change from baseline to the end of the
maintenance phase for each individual cog-
nitive test was also assessed, as were the
percentages  of  patients  whose  results
improved, did not change, or worsened on
each  cognitive  test  and  the  percentage  of
patients who were seizure free during the
dose escalation phase and the maintenance
phase.  Other  study  end  points  were  the
maintenance dosage of study drug, the pro-
portion of patients experiencing drug-relat-
ed treatment-emergent adverse events, and
the overall response to treatment at the end
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the  maintenance  phase,  as  rated  on  a  7-
point  Likert-type  scale.  Using  this  scale,
patients,  family  members,  and  clinicians
rated  overall  response  to  treatment  since
beginning  lamotrigine/topiramate  therapy
as “very much improved,” “much improved,”
“minimally improved,” “no change,” “mini-
mally worsened,” “much worsened,” or “very
much  worsened.”  Family  member  assess-
ments, conducted only when a family mem-
ber was available, were not collected for all
patients.
Statistical methods
The  primary  end  point  of  the  study  (i.e.
change from baseline to the end of the mainte-
nance  phase  in  combined  cognitive  test
results) was analyzed via the O’Brien test
16and
analysis  of  variance  (ANOVA).  Ranks  were
assigned  to  individual  test  results  for  each
patient, with higher scores representing better
cognitive function. A total rank was calculated
for  each  patient  by  adding  the  ranks  of  the
individual tests, and ANOVA was used to test
for differences between the lamotrigine and
topiramate groups in patient total rankings.
Differences  between  treatment  groups  for
individual  cognitive  tests  were  analyzed  via
analysis of covariance (ANCOVA); the change
in score from baseline to the end of the main-
tenance  phase  was  the  dependent  variable,
treatment  and  age  category  were  predictor
variables, and screening score was a covariate.
The  incidence  of  seizure  freedom  was  com-
pared  between  treatment  groups  with  the
Fisher’s exact test. The proportion of patients
citing cognitive decline as the primary reason
for premature study discontinuation was com-
pared between treatment groups with a ˇ
2 test.
For all tests, values of p≤0.05 were considered
significant.  All  other  study  end  points  were
summarized  with  descriptive  statistics.  For
analysis of the patient, family, and clinician
assessment  data,  the  “very  much”,  “much”,
and  “minimally  improved”  responses  were
combined into one category (“improved”), and
the  “very  much”,  “much”,  and  “minimally
worsened” responses were combined into one
category  (“worsened”).  Cognitive  function,
seizure freedom, and patient, family, and clini-
cian  assessment  data  were  evaluated  for
patients  who  completed  the  study.  Adverse
event data were evaluated for all patients.
Results
Demographics, baseline character-
istics, and patient disposition
Fifty-one patients (lamotrigine, n=25; top-
iramate, n=26) were included in the analy-
sis. Baseline demographics and patient char-
acteristics  are  shown  in  Table  2.  Fifteen
patients (60%) in the lamotrigine group and
13  patients  (50%)  in  the  topiramate  group
completed the trial. Reasons for premature
study  discontinuation  included  adverse
event(s)  (lamotrigine,  n=7;  topiramate,
n=9),  withdrawal  of  consent  (lamotrigine,
n=1; topiramate, n=1), lost to follow-up (lam-
otrigine, n=1; topiramate, n=0), protocol vio-
lation (lamotrigine, n=0; topiramate, n=1),
and other reasons (lamotrigine, n=1; topira-
mate,  n=2).  The  median  maintenance
dosage  was  500.0  mg/d  (range,  314.6-500.0
mg/d) for lamotrigine and 300.0 mg/d (range,
262.5-300.0 mg/d) for topiramate.
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Table 1. Dosage escalation schedules for lamotrigine and topiramate.









Patients were assigned randomly, in a 1:1 ratio, to receive either lamotrigine or topiramate.
Table 2. Baseline demographics and characteristics.
Patient characteristics Lamotrigine (n=25)
Age, mean (SD), years 57.7 (8.9) 56.2 (7.0)
Sex, n. (%)
Male 15 (60) 14 (54)
Female 10 (40) 12 (46)
Age at first seizure, mean (SD), years 37.3 (18.5)* 31.1 (19.4)
N. seizures per month, mean (SD) 3.0 (2.4) 2.6 (1.9)
Seizure classification,
† n. (%)
Simple partial 9 (36) 13 (50)
Complex partial 23 (92) 24 (92)
Secondarily generalized 12 (48) 8 (31)
Primary generalized tonic-clonic 1 (4) 3 (12)
AED use (most commonly used AEDs), n. (%)
Carbamazepine 9 (36) 12 (46)
Phenytoin 16 (64) 14 (54)
AED, antiepileptic drug. *Age at first seizure was available for 24 patients in the lamotrigine group.
†Multiple seizure classifications are
possible for the same patient.
Table 3. Cognitive function test results in study completers.
Cognitive Test Change in score from baseline to Week 16, mean (SD) p
Lamotrigine (n=15) Topiramate (n=13)*
Combined analysis 92.5 (21.1) 78.5 (18.8) 0.243
COWA Test 3.2 (6.4) -8.8 (9.1) <0.001
Stroop Color-Word  8.9 (18.3) 10.2 (21.4) 0.835
Interference Test
Digit Cancellation Test,  1.1 (61.6) 46.0 (27.4) 0.038
total minus errors
LGP Test, dominant hand -4.3 (22.5) 19.0 (54.6) 0.496
RAVLT, delayed recall  1.1 (2.6) 2.7 (2.8) 0.044
Symbol-Digit Modalities Test  2.3 (4.6) -5.8 (5.5) <0.001
(correct number)
COWA, Controlled Oral Word Association; LGP, Lafayette Grooved Pegboard; RAVLT, Rey Auditory-Verbal Learning Test. *n=12 for the
combined analysis, Digit Cancellation Test, and Symbol-Digit Modalities Test. For the LGP Test, a lower change score indicates better
cognitive performance. For all other tests, higher change scores indicate better cognitive performance.Cognitive function
For the primary end point (i.e., combined
results of cognitive tests), no significant dif-
ference between treatment groups was noted
in  mean  change  from  baseline  to  Week  16
(Table  3).  However,  significant  differences
between  treatment  groups  were  noted  for
some individual cognitive tests. Changes from
baseline on the COWA Test and the Symbol-
Digit Modalities Test were significantly better
for lamotrigine-treated patients than for topi-
ramate-treated  patients  (Table  3).  However,
changes  from  baseline  on  the  Digit
Cancellation Test and the RAVLT delayed recall
test  were  significantly  better  for  the  topira-
mate  group  than  for  the  lamotrigine  group.
Table  4  shows  the  proportion  of  patients  in
each treatment group who improved, did not
change, or worsened for each of the cognitive
tests. 
Seizure freedom and overall
assessments
No  significant  differences  were  noted
between treatment groups in the proportion of
patients who were seizure free during the dose
escalation phase, the maintenance phase, or
the entire treatment period (Table 5). Patient,
family,  and  clinician  assessments  of  overall
treatment  response  were  generally  similar
between the treatment groups (Table 6).
Adverse events
Study  drug-related  treatment-emergent
adverse events that were reported in ≥5% of
patients in either treatment group and adverse
events that led to study discontinuation in ≥5%
of  patients  in  either  treatment  group  are
shown in Table 7. The proportion of patients
citing cognitive decline as the primary reason
for study discontinuation was not significantly
different between treatment groups (lamotrig-
ine, 0%; topiramate, 15%). 
Discussion
Aging  is  associated  with  physiological
changes that can alter AED metabolism and
pharmacokinetics
2,5 often resulting in higher
plasma concentrations of AEDs. In particular,
plasma concentrations of unbound AEDs tend
to be higher in older adults than in younger
adults,
5 which  may  increase  cognitive  and
other side effects at dosages that are usually
effective and well-tolerated in younger adults.
In addition, older patients tend to take more
medications for other medical illnesses, which
may  cause  cognitive  side  effects  directly  or
interact with their AEDs. Therefore, the con-
ventional assumption is that cognitive effects
of AEDs are amplified in elderly patients when
compared with younger adults, especially with
AEDs  that  more  frequently  cause  cognitive
side effects in younger patients. Results from
previous studies have suggested that overall
topiramate is associated with a greater degree
of cognitive impairment than is lamotrigine.
1,17-
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Table 4. Proportion of patients improving, having no change, or worsening from base-
line to Week 16 for each cognitive test.
Cognitive Test Outcome N. (%) of patients
Lamotrigine (n=15) Topiramate ()*
COWA Test
Improved 11 (73) 2 (13)
No change 2 (13) 0 (0)
Worsened 1 (8) 12 (92)
Stroop Color-Word Interference Test
Improved 10 (67) 8 (62)
No change 0 (0) 0 (0)
Worsened 5 (33) 5 (38)
Digit Cancellation Test, total minus errors
Improved 7 (47) 12 (100)
No change 0 (0) 0 (0)
Worsened 8 (53) 0 (0)
LGP Test, dominant hand
Improved 7 (47) 9 (69)
No change 1 (7) 0 (0)
Worsened 7 (47) 4 (31)
RAVLT, delayed recall 
Improved 9 (60) 10 (77)
No change 2 (13) 1 (8)
Worsened 4 (27) 2 (15)
Symbol-Digit Modalities Test (correct number)
Improved 9 (60) 2 (17)
No change 0 (0) 0 (0)
Worsened 6 (40) 10 (83)
COWA, Controlled Oral Word Association; LGP, Lafayette Grooved Pegboard; RAVLT, Rey Auditory-Verbal Learning Test. *n=12 for the
Digit Cancellation Test and Symbol-Digit Modalities Test.
Table 5. Seizure freedom in study completers.
Study phase N. (%) of patients seizure free p
Lamotrigine (n=15) Topiramate (n=13)
Dose escalation 6 (40) 5 (38) 1.00
Maintenance 6 (40) 6 (46) 1.00
Entire treatment period 5 (33) 4 (31) 1.00
Table 6. Patient, family, and clinician assessments of overall treatment response in sub-
jects who completed the study.
Assessment Lamotrigine, n. (%) Topiramate, n. (%)
Patient n=15 n=12
Improved 10 (67) 8 (67)
No change 3 (20) 4 (33)
Worsened 2 (13) 0 (0)
Family n=9 n=9
Improved 5 (56) 4 (44)
No change 3 (33) 3 (33)
Worsened 1 (11) 2 (22)
Clinician n=15 n=13
Improved 11 (73) 10 (77)
No change 3 (20) 2 (15)
Worsened 1 (7) 1 (8)19 However, one recent study reported that top-
iramate at 50 mg or 200 mg/day was actually
well tolerated in the elderly population.
20
Our study is the first to specifically compare
the cognitive effects of lamotrigine and topira-
mate  in  older  patients.  Although  the  small
sample size for this study precludes definitive
conclusions on efficacy, our patient popula-
tion  tolerated  both  lamotrigine  and  topira-
mate relatively well. In fact, no significant dif-
ference in overall cognitive test scores was
noted in this analysis of older patients, even
though the previous study had shown greater
cognitive impairment associated with topira-
mate therapy than lamotrigine.
9 Nonetheless,
when  individual  test  results  were  analyzed
separately,  significantly  better  scores  were
noted  for  lamotrigine-treated  patients  than
for topiramate-treated patients on the COWA
Test and the Symbol-Digit Modalities Test. On
the  other  hand,  topiramate-treated  patients
had significantly better scores than did lamot-
rigine-treated  patients  on  the  Digit
Cancellation  Test  and  the  RAVLT  delayed
recall  test.  Similarly,  substantially  greater
proportions  of  patients  in  the  lamotrigine
group than in the topiramate group improved
from baseline to Week 16 on the COWA Test
and the Symbol-Digit Modalities Test, where-
as  a  substantially  greater  proportion  of
patients in the topiramate group than in the
lamotrigine  group  improved  on  the  Digit
Cancellation Test. In comparison to the lamot-
rigine group, the topiramate group had a larg-
er proportion of patients who improved from
baseline  to  Week  16  on  the  RAVLT  delayed
recall test and smaller proportions of patients
who  had  no  change  or  worsened.  Notably,
among patients who prematurely terminated
the study, cognitive decline was the primary
reason  for  study  discontinuation  for  more
patients  in  the  topiramate  group  (2  of
13.15%) than in the lamotrigine group (0 of
10). The difference between groups was not
statistically significant, however.
One  important  limitation  of  the  current
study is the small number of patients who are
50 years old or older. The ≥50 year age cut-off
differs from more commonly used age cut-offs
for “elderly” patients (eg, 60 or 65 years). The
age cut-off in the current analysis was mainly
chosen to provide a larger sample size than
would have been obtained with a more tradi-
tional age cut-off of 60 or 65 years. It is also
important  to  note  that  the  present  analysis
investigated the cognitive effects of lamotrig-
ine versus topiramate as adjunctive therapy,
and the results cannot necessarily be extrapo-
lated to monotherapy.
It is not clear why older patients showed dif-
ferent tolerability profiles to younger patients,
but this could possibly be due to their exposure
to other concurrent medications, difference in
dosing and pharmacokinetics, or simply due to
the small sample size of our study. Clinicians
should  consider  cognitive  effects  when  pre-
scribing AEDs, particularly for older patients
who may already be experiencing some degree
of cognitive decline
2,3 and who may be general-
ly  more  susceptible  to  cognitive  effects  of
AEDs.
1-4Results from this study suggest that, in
older patients, lamotrigine may have less of an
impact  on  some  areas  of  cognitive  function
(ie,  verbal  fluency  and  graphomotor  speed),
whereas  topiramate  may  have  less  of  an
impact on other areas (ie, delayed recall of ver-
bal memory and selective attention). 
Although our study does not fully answer cli-
nicians' questions about the relative tolerabil-
ity in cognitive side effects of lamotrigine ver-
sus topiramate in older patients with epilepsy,
it does demonstrate that different areas of cog-
nitive function may be affected by these two
medications. The results further support the
need for evidence based practice rather than
assumptions when counseling AED therapy for
older patients regarding cognitive side effects.
Future comparative study with a larger number
of patients in a monotherapy trial with differ-
ent AEDs would also be beneficial.
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